Milan, Italy (April 22, 2025)

MgShell, an Italian MedTech company specializing in innovative solutions for ocular disease treatment, has successfully closed a €1’140’000 seed funding round. The investment was led by Capital Cell and the key opinion leader Andrea Giani, MD, with important participations from existing investors, including members of Club degli Investitori through Simon Fiduciaria, Italian Angels for Biotech and Bios Line Holding.

The funds will enable MgShell to accelerate the development and pre-clinical validation of its breakthrough technology, support product development, advance business development activities, and strengthen its team.  MgShell will continue working to finalize the development of its technology, with the goal of bringing it to the clinic and providing an innovative solution for doctors and patients.

 

“This investment marks a pivotal milestone in MgShell’s journey, validating the strength of our vision and the disruptive potential of our technology. With the backing of experienced and strategic investors, we are now in a stronger position to accelerate pre-clinical development and move decisively toward clinical validation. Our goal remains clear: to offer innovative, effective treatments for ocular diseases and make a meaningful difference in patients’ lives.” stated Marco Ferroni, CEO of MgShell.

 

Daniel Oliver, Director of Capital Cell, commented: “At Capital Cell, we specialize in identifying high-potential startups at the earliest stages and MgShell fits that profile perfectly. Their approach to ocular drug delivery is both bold and technically compelling. We’re excited to support them in this critical pre-clinical phase and confident in their ability to transform an area of real unmet medical need.”

 

Andrea Giani, investor and key opinion leader, added: “I am convinced that MgShell can revolutionise retinal health, addressing an unmet medical need with its innovative technology. Its approach could reach current standards of efficacy and safety, reducing the treatment burden for patients, caregivers and physicians. It is a pleasure to work with MgShell, given its extensive knowledge and the impressive R&D program led by Marco Ferroni and Francesco De Gaetano.”

 

Enrico Gianotti, Board Member and Champion from Club degli Investitori, stated: “This second round of investment represents a strong vote of confidence in MgShell and will play a crucial role in enabling the company to achieve the strategic milestone of pre-clinical validation within the planned timeline. While we recognize the important steps ahead, we are highly confident that the team’s strength, commitment and expertise will be instrumental in bringing the project to a successful outcome.”

 

Federica Girolami, investor and Champion from Italian Angels for Biotech added: “I believe that MgShell has the potential to revolutionize the ophthalmological field. By advancing a medical device that directly addresses critical unmet needs in retinal health, this initiative has the potential to significantly enhance patient outcomes and quality of life.”

 

“As a physician and scientist, I am interested in developing innovative solutions improving patients’ lives, which is why I am very selective when investing in start-ups. MgShell is creating a revolutionary technology to treat retinal diseases, enhancing the use of current and future medications. I invested in MgShell and I have decided to reinvest after the success of the initial studies, which demonstrate that their technology is poised to become the best in the field.”emphasized Lucio Rovati, investor and CEO of Rottapharm Biotech.

 

Finally, Paolo Tramonti, CEO of Bios Line Holding respectively, added: “After my experience with Next Sight, I recognized in MgShell the same potential for impactful innovation in ophthalmology. Marco and his team have shown strong execution and clear vision, that’s why I chose to invest again.”

 

“From an investment and governance standpoint, MgShell stands out for its solid management and ability to hit key milestones. We’re confident in their direction and long-term value.” concluded Stefano Gallucci, Advisor of Bios Line Holding.

 

About MgShell:

MgShell is an Italian company specializing in the development of drug delivery technologies for the treatment of ocular diseases. Through a pioneering approach, MgShell aims to reshape patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.

 

About Capital Cell:

Capital Cell is the world’s leading alternative investment platform for early-stage biotech and life science companies. Capital Cell was born in 2015 in the scientific ecosystem of Barcelona, with the mission to democratize access to high-impact and generate high-return investments in the life sciences.

 

About Andrea Giani:

Andrea Giani is a medical doctor, retinal specialist and international key opinion leader in the field, with extensive clinical and industry experience, and a strong interest in innovation and technology applied to clinical practice.

 

About Club degli Investitori:

The Club degli Investitori is an association of over 400 entrepreneurs, executives, and professionals who support startups and scaleups founded by Italian entrepreneurs. An investment through the Club is much more than just capital—it means the involvement of a group of international business angels whose network and expertise are worth far more than the money itself. The Club has invested over €70 million in more than 70 companies, which have collectively raised over €2 billion and created more than 6,500 jobs.

 

About Italian Angels for Biotech (IAB):

Italian Angels for Biotech (IAB) is a business angels association, born in 2015 to support life science projects and start-ups through investment and managerial guidance. It brings together more than 40 industry professionals — entrepreneurs, scientists, doctors, and consultants — committed to turning Italian scientific excellence into successful businesses.

 

About Bios Line Holding:

Founded by Paolo Tramonti, Bios Line Holding carries forward the mission that made Bios Line S.p.A. a national leader in the research and production of natural, plant-based products for daily wellbeing. Bios Line Holding invests in companies focused on identifying opportunities for growth and improvement in the life sciences sector, also contributing expertise to enhance the effectiveness and safety of tools and treatments.